Cutaneous and Systemic Leishmaniasis Market

Global Market Study on Cutaneous and Systemic Leishmaniasis : Increase in healthcare expenditure to drive market expansion

Cutaneous And Systemic Leishmaniasis Market Segmented By pentavalent antimonials, antifungal drugs and anti-lesihmanial/antimicrobial drugs in oral, injectable, and topical Route of Administration with cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis Indication

  • June-2022
  • PMRREP28225
  • 215 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Cutaneous & Systemic Leishmaniasis Market Outlook (2022 - 2028)

The Global Cutaneous & Systemic Leishmaniasis Market value is projected to exceed US$ 411.1 million by the year 2028 at a steady CAGR of 2.90%. The increasing prevalence of Cutaneous & Systemic Leishmaniasis in tropical regions and the growing awareness regarding prevention and treatment of the disease are the major factors driving the growth of this market.

Cutaneous & Systemic Leishmaniasis Market Size (2022)

US$ 345.4 Mn

Projected Market Value (2028)

US$ 411.1 Mn

Global Market Growth Rate (2022-2028)

2.90% CAGR

Share in parent market

0.80%

Find Out More about the Report Coverage

Companies

  • GlaxoSmithKline plc.
  • Gilead Sciences, Inc.
  • Profounda Pharmaceuticals
  • Knight Therapeutics Inc.
  • Janssen Global Services, LLC
  • Albert David Ltd
  • Jubilant Life Sciences Ltd.
  • Novartis AG
  • Sanofi
  • Endo Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • United Biotech Pvt. Ltd.

Cutaneous & Systemic Leishmaniasis Market Demand Analysis (2013-2021) v/s Market Outlook (2022 – 2028)

Cutaneous & Systemic Leishmaniasis is a disease that is prevalent mostly in the tropical regions. Rise in per capita income, increased awareness about the disease, increase in the healthcare expenditure, as well as an increase in the investments for research purposes are driving market growth and are expected to do the same throughout the forecast period.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

What is expected to keep the Hopes High for Cutaneous & Systemic Leishmaniasis Market?

  • “High Clinical Cure Rate with Combinational Drug Therapy”

A combination of several cutaneous and systemic leishmaniasis drugs has resulted in a higher percentage of effectiveness among several cutaneous and systemic trial groups that were treated with medications. Some combinations have also resulted in curing cutaneous and systemic leishmaniasis completely. Hence, this factor is likely to drive the growth of the Cutaneous and Systemic Leishmaniasis Market throughout the forecast period.

cutaneous-and-systemic-leishmaniasis-market

  • “Increased Investments for Research And Development”

Several players in the cutaneous and systemic leishmaniasis markets are substantially investing in research activities to develop novel treatment alternatives. Furthermore, a wide range of drugs and therapies for the treatment of cutaneous and systemic leishmaniasis are currently under clinical trials, with almost all trial outcomes expected to be good. These initiatives are expected to create new opportunities for the treatment of cutaneous and systemic leishmaniasis.

  • “Favorable Reimbursement Policies”

Several governments around the globe are investing heavily in healthcare infrastructure and this is likely to drive the market for cutaneous and systemic leishmaniasis. Apart from this, several private health insurance providers are providing several reimbursement policies for the seamless and successful treatment of cutaneous and systemic leishmaniasis. Furthermore, people now have the freedom to select the type of reimbursement policy that is likely to provide the most advantages.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

What restraints is the Cutaneous & Systemic Leishmaniasis Market subject to?

  • “High Cost of Treatment and Chances Of Side Effects”

The treatment of Cutaneous & Systemic Leishmaniasis is very high due to the drugs being very expensive. Apart from this, the drugs used for the treatment can also cause serious adverse effects. However, new treatment options are being developed and it is expected to give a high degree of therapeutic measures against these diseases and also reduce the side effects.

Explore Persistence Market Research’s expertise in promulgation of the business !

How has Covid-19 affected the Cutaneous & Systemic Leishmaniasis Market?

“Decrease in the Demand of Cutaneous & Systemic Leishmaniasis due to lockdown”

The covid-19 outbreak had a negative impact on the global economy and it hurt the growth of the Cutaneous & Systemic Leishmaniasis Market because there was a drop in the demand for Cutaneous & Systemic Leishmaniasis drugs and treatment because healthcare facilities around the world were burdened with millions of Covid-19 positive patients. However, the demand increased again when the situation improved in 2021.

Competitive Landscape

The Cutaneous & Systemic Leishmaniasis market is highly competitive and consists of significant major players that dominate the market. Several market players are implementing new and differentiating strategies to meet product demand and dominate the regional market. The market players are focusing on adopting new strategies and policies, such as effective technological & distributorship collaborations, promoting research & development for the development of products for the treatment of cutaneous & systemic leishmaniasis and product lunches, etc.

Cutaneous & Systemic Leishmaniasis Market Industry Report Scope

Attribute

Details

Forecast Period

2022-2028

Historical Data Available for

2013-2021

Market Analysis

US$ Mn/Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Germany
  • Italy
  • France
  • U.K.
  • Spain
  • Russia
  • India
  • China
  • Japan
  • UAE
  • Australia

Key Market Segments Covered

By Distribution Channel

Key Companies Profiled

  • Gilead Sciences, Inc.
  • Profounda Pharmaceuticals
  • Knight Therapeutics Inc.
  • Janssen Global Services, LLC
  • Albert David Ltd
  • Jubilant Life Sciences Ltd.
  • Novartis AG
  • Sanofi
  • Endo Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • United Biotech Pvt. Ltd.

Customization & Pricing

Available upon Request

Cutaneous & Systemic Leishmaniasis Market Categorization

Cutaneous & Systemic Leishmaniasis Market by By Drug Class

  • Pentavalent Antimonials
  • Antifungal Drugs
  • Anti-Lesihmanial/Antimicrobial Drugs

Cutaneous & Systemic Leishmaniasis Market By Route of Administration

  • Oral
  • Injectable
  • Topical

Cutaneous & Systemic Leishmaniasis Market By Indication

  • Cutaneous Leishmaniasis
  • Mucosal Leishmaniasis
  • Visceral Leishmaniasis

Cutaneous & Systemic Leishmaniasis Market By Distribution Channel

  • Hospital Pharmacies,
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Cutaneous & Systemic Leishmaniasis Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Media Release

- FAQs -

In 2022, the Cutaneous & Systemic Leishmaniasis Market stands at USD 345.4 million, and it is expected to reach USD 411.1 million by 2028 at a CAGR of 2.90%.

Cutaneous & Systemic Leishmaniasis Market exhibited a 2.90% CAGR between 2013 and 2021.

High Cost of Treatment and Chances Of Side Effects are the key restraints in the Cutaneous & Systemic Leishmaniasis Market.

High Clinical Cure Rate with Combinational Drug Therapy and Increased Investments for Research are the key factors driving the growth of the market.

Gilead Sciences Inc., Profounda Pharmaceuticals, Knight Therapeutics Inc., Janssen Global Services LLC, and Albert David Ltd, are among the top players in the market.

Recommendations

Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market is largely dominated by large vendors who are competing on the basis of market penetration and distribution.Companies, such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., hold more than 50% revenue share in the global post herpetic neuralgia treatment market..

Pharmaceutical Excipients Market

Pharmaceutical Excipients Market was valued at US$ 5,682.7 Mn in 2017 and is anticipated to reach a valuation of US$ 7,415.2 Mn in 2021 end, displaying a CAGR of 6.9% during the period of assessment 2017-2021..

Meningococcal Vaccines Market

The Global Meningococcal Vaccines market is expected to have a significant CAGR of 13.1% by 2028..

Medical Foods Market

The North American medical foods market is a prominent market on a global level, with the adoption of medical foods comparatively high in the. Health practitioners present here prescribe medical foods over other routine foods to overcome diseases at a much faster pace..

Our Clients

Our Clients